Table 1.
Demographics and disease characteristics of the blinded extension population at study entry.
| Placebo → ozanimod HCl 0.5 mg, (n = 41) | Ozanimod HCl 0.5 mg → ozanimod HCl 0.5 mg, (n = 85) | Placebo → ozanimod HCl 1 mg, (n = 42) | Ozanimod HCl 1 mg → ozanimod HCl 1 mg, (n = 81) | |
|---|---|---|---|---|
| Mean age (SD), years | 41 (8.01) | 38.1 (9.26) | 36.9 (8.69) | 38.5 (9.90) |
| Female, n (%) | 30 (73.2) | 58 (68.2) | 30 (71.4) | 57 (70.4) |
| White, n (%) | 41 (100) | 83 (97.6) | 42 (100) | 81 (100) |
| Eastern Europe, n (%) | 38 (92.7) | 78 (91.8) | 36 (85.7) | 74 (91.4) |
| Mean time since MS symptom onset (SD), years | 9.0 (7.05) | 6.0 (6.49) | 7.0 (7.05) | 6.2 (5.81) |
| Mean time since MS diagnosis (SD), years | 5.3 (5.19) | 2.8 (5.02) | 3.7 (5.11) | 3.6 (4.46) |
| Mean EDSS score (SD) | 2.7 (1.19) | 2.9 (1.29) | 2.9 (1.38) | 2.8 (1.18) |
| Mean relapses in the previous 12 months, n (SD) | 1.3 (0.68) | 1.4 (0.95) | 1.4 (0.62) | 1.3 (0.71) |
| Mean relapses in the previous 24 months, n (SD) | 2.0 (1.22) | 2.0 (1.69) | 1.7 (0.75) | 1.8 (1.05) |
| Mean gadolinium-enhancing lesions, n (SD) | 1.8 (3.73) | 0.9 (1.43) | 0.6 (1.38) | 1.4 (2.78) |
| Participants free of gadolinium-enhancing lesions, n (%) | 28 (68.3) | 51 (60.0) | 30 (71.4) | 51 (63.0) |
| Participants who received prior MS medication, n (%) | 18 (43.9) | 19 (22.4) | 12 (28.6) | 18 (22.2) |
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; SD: standard deviation.
Demographic and baseline characteristics at entry into the double-blind, placebo-controlled phase of RADIANCE Part A.